No qualifying author-owned investment thesis was confirmed in this post.
no investment thesis
▶ Full Post Text
In the shadowy pre-market theater, NCI opens at $3.80 down 6.98% amid broader weakness, yesterday's 834K volume a mere whisper vs 3-month avg 2.8M (0.3x). Yet beneath the curtain, the real act is NCI's poised recovery above 50MA $1.39 and 200MA $1.69, P/E 14.6 intact.
Enter stage left: the $8.1M equity offering finale on Feb 11, issuing 14.85M shares at $0.5454 through D. Boral Capital for grand business expansion - the spark behind the 36% surge from $0.72 to $2.39, per Timothy Sykes analysis. Revenue growth pressures (-24% YoY) unchanged, but this capital infusion hints at upcoming plot twists. Past dips have mystically reversed, especially with pre-market positioning.
Will NCI's directors cue the applause on open? What's your read on the post-offering momentum?
Not financial advice - purely speculative theater.